OCGN
Ocugen, Inc.
$1.26
-1.56%
$426.5M
No data for this timeframe.
Vol
Market Cap$426.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders8 funds
Inst. Value$26.7M
Inst. Activity4 buys / 1 sells
Reddit Sentiment80° Bullish
SEC Reports6
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001372299·Prev Close $1.28
Recent Activity
Jun 8, 2026
short_volume
Short Volume: OCGN — 56.5% short (0.9M / 1.6M)
Short: 901,290 | Exempt: 17,954 | TRF Vol: 1,595,081 | Short Ratio: 56.5% | Off-exchange volume (dar
May 5, 2026
SEC
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5
8-K — Impact 6/10
May 5, 2026
SEC
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss w
PRESS-RELEASE — Impact 6/10
May 4, 2026
SEC
Ocugen announced a private offering of $115M convertible senior notes due 2034 (plus $15M option), intending to use ~$32
8-K — Impact 6/10
Apr 1, 2026
Insider
Zhang Junge sold 15,000 shares
Director @ $0.5100 ($7.7K)
Apr 1, 2026
Insider
Zhang Junge sold 15,000 shares
Director @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
1,700,400 shares ($2.3M)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
678,547 shares ($916.0K)
Price Targets
$11.43
+821.7% upside
Strong Buy
Current $1.24
Low $7.00
Median $10.00
High $22.00
7 analysts
$7.00
$22.00
Analyst Ratings
3Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 11, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▼ -3.2% | $-0.06 — $-0.04 | -7% YoY | 6 |
| Next Q | $-0.05 | $-0.06 — $-0.04 | 24% YoY | 6 |
| Current FY | $-0.22 ▼ -3.9% | $-0.25 — $-0.18 | 3% YoY | 6 |
| Next FY | $-0.23 ▼ -634.1% | $-0.26 — $-0.18 | -5% YoY | 4 |
Latest Reports
MIXED
8-K
6/10
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5
May 5, 2026
MIXED
PRESS-RELEASE
6/10
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss w
May 5, 2026
BEARISH
Press
7/10
Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $22.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $2.3M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $916.0K | DOUBLED |
| MORGAN STANLEY | $625.7K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $231.8K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Zhang Junge | M | $7.7K |
| Apr 1, 2026 | Zhang Junge | M | $0.00 |
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
8 institutional holders with $26.7M total value (19,743,195 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 16,475,562 | $22.2M | 83.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,700,400 | $2.3M | 8.6% | DOUBLED +485.9% |
| 3 | TWO SIGMA INVESTMENTS, LP | 678,547 | $916.0K | 3.4% | DOUBLED +828.4% |
| 4 | MORGAN STANLEY | 463,454 | $625.7K | 2.3% | ADD +59.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 171,723 | $231.8K | 0.9% | NEAR_EXIT -80.0% |
| 6 | FMR LLC | 150,836 | $203.6K | 0.8% | TRIM -40.6% |
| 7 | BANK OF AMERICA CORP /DE/ | 98,672 | $133.2K | 0.5% | TRIM -36.1% |
| 8 | WELLS FARGO & COMPANY/MN | 4,001 | $5.4K | 0.0% | DOUBLED +273.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 290,200 | 1,700,400 | +485.9% | $2.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 73,088 | 678,547 | +828.4% | $916.0K | 2025-Q4 |
| MORGAN STANLEY | ADD | 290,564 | 463,454 | +59.5% | $625.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 154,372 | 98,672 | -36.1% | $133.2K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,070 | 4,001 | +273.9% | $5.4K | 2025-Q4 |
| UBS Group AG | ADD | 654,379 | 1,024,879 | +56.6% | $1.7M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 611,698 | 290,564 | -52.5% | $473.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 290,200 | — | $473.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 81,199 | 154,372 | +90.1% | $251.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 73,088 | — | $119.1K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 11,497 | 1,070 | -90.7% | $1.7K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 4,367,780 | 654,379 | -85.0% | $634.7K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 843,397 | 611,698 | -27.5% | $593.6K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 860,244 | 171,723 | -80.0% | $166.6K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 141,533 | 81,199 | -42.6% | $78.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 147,257 | 11,497 | -92.2% | $11.2K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 3,459,283 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | DOUBLED | 974,643 | 4,367,780 | +348.1% | $3.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 2,087,632 | 3,459,283 | +65.7% | $2.4M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 566,487 | 328,368 | -42.0% | $231.9K | 2025-Q1 |
| FMR LLC | TRIM | 224,025 | 133,000 | -40.6% | $93.9K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 319,795 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 2,087,632 | — | $1.7M | 2024-Q4 |
| UBS Group AG | ADD | 568,867 | 974,643 | +71.3% | $784.6K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 86,838 | 141,773 | +63.3% | $114.1K | 2024-Q4 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Zhang Junge | Director | M | 15,000 | $0.5100 | $7.7K |
| Apr 1, 2026 | Zhang Junge | Director | M | 15,000 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 5 mixed, 1 neutral. Avg impact: 5.3/10.
MIXED
8-K
6/10
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrange
May 5, 2026
MIXED
PRESS-RELEASE
6/10
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (
May 5, 2026
MIXED
8-K
6/10
Ocugen announced a private offering of $115M convertible senior notes due 2034 (plus $15M option), i
May 4, 2026
NEUTRAL
PRESS-RELEASE
2/10
Ocugen announced it will release Q1 2026 financial results on May 5, 2026, with a conference call. N
Apr 29, 2026
MIXED
8-K
6/10
Ocugen filed a petition in Delaware Court of Chancery seeking validation of a corporate action that
Mar 4, 2026
MIXED
8-K
6/10
Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net
Mar 4, 2026
BEARISH
7/10
Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net pr
May 5, 2026
BULLISH
8/10
Ocugen announced positive 12-month Phase 2 data for OCU410, its gene therapy for geographic atrophy
Mar 24, 2026
MIXED
6/10
Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider n
Mar 4, 2026
BULLISH
8/10
Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therap
Mar 2, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 3 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.43 mean target
+821.7% upside
Strong Buy (1.14)
$7.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $1.24 |
| Target Low | $7.00 |
| Target Mean | $11.43 |
| Target Median | $10.00 |
| Target High | $22.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.04 | -6.7% | -3.2% | 2↑ 3↓ | $0.0B | -35.7% | 6 |
| Next Q 2026-09-30 |
$-0.05 | $-0.06 | $-0.04 | 23.8% | +0.0% | 2↑ 4↓ | $0.0B | -51.5% | 6 |
| Current FY 2026-12-31 |
$-0.22 | $-0.25 | $-0.18 | 2.9% | -3.9% | 2↑ 4↓ | $0.0B | -7.6% | 6 |
| Next FY 2027-12-31 |
$-0.23 | $-0.26 | $-0.18 | -5.2% | -634.1% | 1↑ 3↓ | $0.0B | 170.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.053 | |
| 7d ago | $-0.052 | -0.002 |
| 30d ago | $-0.052 | -0.002 |
| 60d ago | $-0.052 | -0.002 |
| 90d ago | $-0.057 | +0.003 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 11, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
thought on this ?
▲ 1
💬 1
⚡ 0.5
OCGN $30 - Oppenheimer Initiates Coverage
▲ 1
💬 1
⚡ 0.5
YOLO'ED Into OCGN ( Ocugen Inc ) & WON
▲ 1
💬 0
⚡ 0.5
YOLO'ED Into OCGN ( Ocugen, Inc ) & WON !!!
▲ 1
💬 0
⚡ 0.5
What’s your input?
▲ 1
💬 1
⚡ 0.5
Jun 8, 2026
short_volume
Short Volume: OCGN — 56.5% short (0.9M / 1.6M)
Short: 901,290 | Exempt: 17,954 | TRF Vol: 1,595,081 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: OCGN — 60.3% short (1.5M / 2.5M)
Short: 1,520,186 | Exempt: 1,153 | TRF Vol: 2,519,459 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: OCGN — 56.0% short (1.2M / 2.1M)
Short: 1,163,709 | Exempt: 4,312 | TRF Vol: 2,078,350 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
Ocugen to Participate in Upcoming June Investor and Industry Conferences
<p align="left">MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology lead
Jun 2, 2026
short_volume
Short Volume: OCGN — 60.8% short (1.4M / 2.3M)
Short: 1,400,986 | Exempt: 298 | TRF Vol: 2,303,410 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: OCGN — 65.1% short (1.9M / 2.9M)
Short: 1,868,639 | Exempt: 293,730 | TRF Vol: 2,869,498 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: OCGN — 83.0% short (8.1M / 9.8M)
Short: 8,127,839 | Exempt: 5,800 | TRF Vol: 9,791,827 | Short Ratio: 83.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: OCGN — 56.9% short (1.5M / 2.7M)
Short: 1,546,034 | Exempt: 69 | TRF Vol: 2,715,826 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: OCGN — 56.5% short (1.6M / 2.8M)
Short: 1,584,579 | Exempt: 756 | TRF Vol: 2,806,076 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: OCGN — 61.5% short (1.3M / 2.1M)
Short: 1,285,947 | Exempt: 2,122 | TRF Vol: 2,092,201 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: OCGN — 57.2% short (1.5M / 2.7M)
Short: 1,541,587 | Exempt: 16 | TRF Vol: 2,693,135 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
other
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Includes Full Exercise of $15.0 million Over-Allotment Option <pre>Includes Full Exercise of $15.0 million Over-Allotment Option</pre>
May 14, 2026
short_volume
Short Volume: OCGN — 58.1% short (1.4M / 2.4M)
Short: 1,394,953 | Exempt: 21,626 | TRF Vol: 2,402,065 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
<p>MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene the
May 12, 2026
short_volume
Short Volume: OCGN — 56.5% short (2.0M / 3.6M)
Short: 2,012,795 | Exempt: 5,897 | TRF Vol: 3,563,206 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)